{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:21:00Z","timestamp":1775251260052,"version":"3.50.1"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Sci-Tech Special Project of China","award":["2018ZX10302207"],"award-info":[{"award-number":["2018ZX10302207"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2018YFC1313304"],"award-info":[{"award-number":["2018YFC1313304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science and Technology Commission Program","award":["Z141107002514013"],"award-info":[{"award-number":["Z141107002514013"]}]},{"name":"National Key Research and Development Program of China","award":["2017YFC1308900"],"award-info":[{"award-number":["2017YFC1308900"]}]},{"DOI":"10.13039\/501100015850","name":"Digestive Medical Coordinated Development Center of Beijing Hospitals Authority","doi-asserted-by":"crossref","award":["XXT19"],"award-info":[{"award-number":["XXT19"]}],"id":[{"id":"10.13039\/501100015850","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,6,5]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the great achievements made in immune-checkpoint-blockade (ICB) in cancer therapy, there are no effective predictive biomarkers in gastrointestinal (GI) cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included 93 metastatic GI patients treated with ICBs. The first cohort comprising 73\u2009GI cancer patients were randomly assigned into discovery (n=44) and validation (n=29) cohorts. Comprehensive genomic profiling was performed on all samples to determine tumor mutational burden (TMB) and copy-number alterations (CNAs). A subset of samples was collected for RNA immune oncology (IO) panel sequencing, microsatellite instability (MSI)\/mismatch repair and program death ligand 1 (PD-L1) expression evaluation. In addition, 20 gastric cancer (GC) patients were recruited as the second validation cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the first cohort of 73\u2009GI cancer patients, a lower burden of CNA was observed in patients with durable clinical benefit (DCB). In both the discovery (n=44) and validation (n=29) subsets, lower burden of CNA was associated with an improved clinical benefit and better overall survival (OS). Efficacy also correlated with a higher TMB. Of note, a combinatorial biomarker of TMB and CNA may better stratify DCB patients from ICB treatment, which was further confirmed in the second validation cohort of 20 GC patients. Finally, patients with lower burden of CNA revealed increased immune signatures in our cohort and The Cancer Genome Atlas data sets as well.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that the burden of CNA may have superior predictive value compared with other signatures, including PD-L1, MSI and TMB. The joint biomarker of CNA burden and TMB may better stratify DCB patients, thereby providing a rational choice for GI patients treated with ICBs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000374","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T10:21:56Z","timestamp":1597400516000},"page":"e000374","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":60,"title":["Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer"],"prefix":"10.1136","volume":"8","author":[{"given":"Zhihao","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Genecast Precision Medicine Technology Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianling","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Wu","sequence":"additional","affiliation":[{"name":"Genecast Precision Medicine Technology Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Yu","sequence":"additional","affiliation":[{"name":"Genecast Precision Medicine Technology Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Han","sequence":"additional","affiliation":[{"name":"Genecast Precision Medicine Technology Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaibo","family":"Sun","sequence":"additional","affiliation":[{"name":"Genecast Precision Medicine Technology Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025100315151526000_8.2.e000374.1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.7150\/jca.18470","article-title":"Current status of immune checkpoint inhibitors in gastrointestinal cancers","volume":"8","author":"Kim","year":"2017","journal-title":"J Cancer"},{"key":"2025100315151526000_8.2.e000374.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2025100315151526000_8.2.e000374.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332"},{"key":"2025100315151526000_8.2.e000374.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.026"},{"key":"2025100315151526000_8.2.e000374.5","doi-asserted-by":"publisher","DOI":"10.4132\/KoreanJPathol.2013.47.1.28"},{"key":"2025100315151526000_8.2.e000374.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213"},{"key":"2025100315151526000_8.2.e000374.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2025100315151526000_8.2.e000374.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100315151526000_8.2.e000374.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1508163"},{"key":"2025100315151526000_8.2.e000374.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"2025100315151526000_8.2.e000374.11","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"2025100315151526000_8.2.e000374.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01018-0"},{"key":"2025100315151526000_8.2.e000374.13","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025100315151526000_8.2.e000374.14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.08.001","article-title":"Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing","volume":"120","author":"Kim","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100315151526000_8.2.e000374.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526613","article-title":"Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden","volume":"7","author":"Budczies","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100315151526000_8.2.e000374.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2025100315151526000_8.2.e000374.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"key":"2025100315151526000_8.2.e000374.18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts146"},{"key":"2025100315151526000_8.2.e000374.19","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.18632\/oncotarget.13691","article-title":"Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing","volume":"8","author":"Paluch","year":"2017","journal-title":"Oncotarget"},{"key":"2025100315151526000_8.2.e000374.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2025100315151526000_8.2.e000374.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460"},{"key":"2025100315151526000_8.2.e000374.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07767-w"},{"key":"2025100315151526000_8.2.e000374.23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2025100315151526000_8.2.e000374.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100315151526000_8.2.e000374.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"2025100315151526000_8.2.e000374.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100315151526000_8.2.e000374.27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.21037\/jgo.2016.07.03","article-title":"Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others","volume":"7","author":"Bupathi","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"2025100315151526000_8.2.e000374.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025100315151526000_8.2.e000374.29","unstructured":"Tabernero J , Cutsem EV , Bang Y-J , et al . KEYNOTE-062: phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology 2019."},{"key":"2025100315151526000_8.2.e000374.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2025100315151526000_8.2.e000374.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"2025100315151526000_8.2.e000374.32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"},{"key":"2025100315151526000_8.2.e000374.33","doi-asserted-by":"crossref","first-page":"v916","DOI":"10.1093\/annonc\/mdz394.077","article-title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials","volume":"30","author":"Herbst","year":"2019","journal-title":"Annals of Oncology"},{"key":"2025100315151526000_8.2.e000374.34","doi-asserted-by":"crossref","first-page":"v917","DOI":"10.1093\/annonc\/mdz394.078","article-title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Annals of Oncology"},{"key":"2025100315151526000_8.2.e000374.35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37294","article-title":"Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death","volume":"7","author":"Hieronymus","year":"2018","journal-title":"Elife"},{"key":"2025100315151526000_8.2.e000374.36","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00421"},{"key":"2025100315151526000_8.2.e000374.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2014.09.003"},{"key":"2025100315151526000_8.2.e000374.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.026"},{"key":"2025100315151526000_8.2.e000374.39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1219580"},{"key":"2025100315151526000_8.2.e000374.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1411446111"},{"key":"2025100315151526000_8.2.e000374.41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007"},{"key":"2025100315151526000_8.2.e000374.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2128"},{"key":"2025100315151526000_8.2.e000374.43","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2025100315151526000_8.2.e000374.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0558"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:15:23Z","timestamp":1759529723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jitc-2019-000374"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000374","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}